UBS Group
EGRX

UBS Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

UBS Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-480
Closed -$1.79K – 10759
2024
Q3 		$1.79K Sell
480
-2
-0.4% -$10 ﹤0.01% 8552
2024
Q2 		$2.7K Sell
482
-11,707
-96% -$51K ﹤0.01% 8311
2024
Q1 		$63.9K Buy
12,189
+3,818
+46% +$21K ﹤0.01% 6405
2023
Q4 		$43.8K Sell
8,371
-9,501
-53% -$93.8K ﹤0.01% 6618
2023
Q3 		$282K Sell
17,872
-19,410
-52% -$349K ﹤0.01% 5109
2023
Q2 		$725K Buy
37,282
+26,563
+248% +$630K ﹤0.01% 4517
2023
Q1 		$304K Sell
10,719
-34,964
-77% -$1.04M ﹤0.01% 5076
2022
Q4 		$1.34M Buy
45,683
+35,780
+361% +$1.14M ﹤0.01% 3793
2022
Q3 		$261K Buy
9,903
+1,388
+16% +$50.9K ﹤0.01% 4871
2022
Q2 		$378K Sell
8,515
-18,549
-69% -$852K ﹤0.01% 4475
2022
Q1 		$1.34M Sell
27,064
-6,648
-20% -$319K ﹤0.01% 3820
2021
Q4 		$1.72M Buy
33,712
+10,508
+45% +$544K ﹤0.01% 3876
2021
Q3 		$1.29M Buy
23,204
+15,103
+186% +$743K ﹤0.01% 3962
2021
Q2 		$347K Sell
8,101
-13,178
-62% -$544K ﹤0.01% 4982
2021
Q1 		$888K Buy
21,279
+21,229
+42,458% +$986K ﹤0.01% 4380
2020
Q4 		$2K Hold
50
– – ﹤0.01% 8134
2020
Q3 		$2K Hold
50
– – ﹤0.01% 7707
2020
Q2 		$2K Sell
50
-3,429
-99% -$171K ﹤0.01% 7672
2020
Q1 		$160K Sell
3,479
-2,199
-39% -$110K ﹤0.01% 4896
2019
Q4 		$342K Sell
5,678
-20,760
-79% -$1.24M ﹤0.01% 5179
2019
Q3 		$1.5M Sell
26,438
-15,477
-37% -$870K ﹤0.01% 3600
2019
Q2 		$2.33M Buy
41,915
+38,608
+1,167% +$2.01M ﹤0.01% 3005
2019
Q1 		$167K Sell
3,307
-77,885
-96% -$3.47M ﹤0.01% 4732
2018
Q4 		$3.27M Buy
81,192
+69,367
+587% +$3.57M ﹤0.01% 2550
2018
Q3 		$820K Buy
11,825
+11,346
+2,369% +$860K ﹤0.01% 4025
2018
Q2 		$36K Sell
479
-47,501
-99% -$2.99M ﹤0.01% 6262
2018
Q1 		$2.53M Buy
47,980
+37,597
+362% +$2.19M ﹤0.01% 2936
2017
Q4 		$554K Sell
10,383
-17,186
-62% -$956K ﹤0.01% 4220
2017
Q3 		$1.64M Buy
27,569
+13,914
+102% +$842K ﹤0.01% 3295
2017
Q2 		$1.08M Buy
13,655
+12,318
+921% +$1.01M ﹤0.01% 3555
2017
Q1 		$111K Sell
1,337
-18,347
-93% -$1.36M ﹤0.01% 5010
2016
Q4 		$1.56M Buy
19,684
+15,469
+367% +$1.12M ﹤0.01% 3136
2016
Q3 		$295K Sell
4,215
-13,607
-76% -$754K ﹤0.01% 4277
2016
Q2 		$692K Buy
17,822
+8,726
+96% +$363K ﹤0.01% 3658
2016
Q1 		$368K Sell
9,096
-22,009
-71% -$1.4M ﹤0.01% 4014
2015
Q4 		$2.76M Buy
31,105
+24,177
+349% +$1.91M ﹤0.01% 2504
2015
Q3 		$513K Buy
6,928
+1,255
+22% +$104K ﹤0.01% 3875
2015
Q2 		$458K Buy
+5,673
New +$370K ﹤0.01% 4200

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

UBS Group's EGRX Position: Q4 2024 in Review

UBS Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 480 shares — an estimated $1.79K sold.

UBS Group first reported a position in EGRX in Q2 2015 and held it in 38 quarters. The position peaked at $3.27M in Q4 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • UBS Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • UBS Group sold 480 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $1.79K.
  • UBS Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 38 quarters.
  • UBS Group's Eagle Pharmaceuticals, Inc. position peaked at $3.27M in Q4 2018.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.